Experience of L-carnitine use in the treatment of non-alcoholic fatty liver disease
Nowadays non-alcoholic fatty liver disease is one of the most widespread diseases in hepatology, leading to life deterioration, disability and death rate that first of all is caused by high progressing risk with development of hepatic insufficiency and hepatocellular carcinoma. The aim of this article is to determine the possibility of L-carnitine using in the treatment of steatohepatitis in patients with non-alcoholic fatty liver disease.